Repurposing ribosome-targeting antibiotics to overcome resistance to venetoclax in acute myeloid leukemia

被引：1
|
作者：
Sharon, David [1 ]
Chan, Steven M. [1 ]
机构：
[1] Princess Margaret Canc Ctr, Dept Hematol & Med Oncol, Toronto, ON, Canada
来源：
MOLECULAR & CELLULAR ONCOLOGY | 2020年 / 7卷 / 02期
基金：
加拿大健康研究院;
关键词：
Acute myeloid leukemia; BCL-2; inhibitor; drug resistance; integrated stress response; antibiotics; mitochondrial translation; ABT-199;
D O I：
10.1080/23723556.2020.1712182
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Venetoclax, a selective B-cell lymphoma 2 inhibitor, has shown promise in the treatment of acute myeloid leukemia. However, the development of drug resistance limits its clinical efficacy. In our study, we discovered that ribosome-targeting antibiotics can be repurposed to overcome venetoclax resistance in AML cells through activation of the integrated stress response.
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
    Jonas, Brian A.
    Hou, Jing-Zhou
    Roboz, Gail J.
    Alvares, Caroline L.
    Jeyakumar, Deepa
    Edwards, John R.
    Erba, Harry P.
    Kelly, Richard J.
    Roellig, Christoph
    Fiedler, Walter
    Brackman, Deanna
    Siddani, Satya R.
    Chyla, Brenda
    Hilger-Rolfe, Jacqueline
    Watts, Justin M.
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 743 - 752
  • [32] Drug Repurposing for the Treatment of Acute Myeloid Leukemia
    Andresen, Vibeke
    Gjertsen, Bjorn T.
    FRONTIERS IN MEDICINE, 2017, 4
  • [33] Targeting Abnormally Increased Expression of ULK1 Sensitizes Acute Myeloid Leukemia Resistant Cells to Venetoclax
    Betz, Heather
    Jiang, Xiaoyan
    BLOOD, 2023, 142
  • [34] Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
    Garciaz, Sylvain
    Hospital, Marie-Anne
    Alary, Anne-Sophie
    Saillard, Colombe
    Hicheri, Yosr
    Mohty, Bilal
    Rey, Jerome
    D'Incan, Evelyne
    Charbonnier, Aude
    Villetard, Ferdinand
    Maisano, Valerio
    Lombardi, Laura
    Ittel, Antoine
    Mozziconacci, Marie-Joelle
    Gelsi-Boyer, Veronique
    Vey, Norbert
    CANCERS, 2022, 14 (08)
  • [35] Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia
    Lachowiez, Curtis A.
    Atluri, Himachandana
    DiNardo, Courtney D.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [36] Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
    Nwosu, Gus O.
    Ross, David M.
    Powell, Jason A.
    Pitson, Stuart M.
    CELL DEATH & DISEASE, 2024, 15 (06):
  • [37] Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors
    Sorf, Ales
    Sucha, Simona
    Morell, Anselm
    Novotna, Eva
    Staud, Frantisek
    Zavrelova, Alzbeta
    Visek, Benjamin
    Wsol, Vladimir
    Ceckova, Martina
    CANCERS, 2020, 12 (06) : 1 - 15
  • [38] Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms
    Carter, Jenna L.
    Su, Yongwei
    Qiao, Xinan
    Zhao, Jianlei
    Wang, Guan
    Howard, Mackenzie
    Edwards, Holly
    Bao, Xun
    Li, Jing
    Huettemann, Maik
    Yang, Jay
    Taub, Jeffrey W.
    Ge, Yubin
    BIOCHEMICAL PHARMACOLOGY, 2023, 216
  • [39] Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
    Teh, T-C
    Nguyen, N-Y
    Moujalled, D. M.
    Segal, D.
    Pomilio, G.
    Rijal, S.
    Jabbour, A.
    Cummins, K.
    Lackovic, K.
    Blombery, P.
    Thompson, E.
    Ekert, P. G.
    Lessene, G.
    Glaser, S. P.
    Huang, D. C. S.
    Roberts, A. W.
    Guthridge, M. A.
    Wei, A. H.
    LEUKEMIA, 2018, 32 (02) : 303 - 312
  • [40] How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia
    Maiti, Abhishek
    Konopleva, Marina Y.
    CANCER JOURNAL, 2022, 28 (01) : 2 - 13
12345